

Antimicrobial Susceptibilities of Clinical Bacterial Isolates from Urinary Tract Infections to Fosfomycin and Comparator Antibiotics Determined by Agar Dilution Method and Automated Micro Broth Dilution

¹Jamie L Dombach, ²Nancy Smith, ²Teresa Kottiri, ¹Alicia Schiller, ^{2,3}Edwin Kamau[#]

¹Department of Clinical Investigations, Tripler Army Medical Center, Honolulu, HI, USA

²Department of Pathology and Area Laboratory Services, Walter Reed National Military Medical Center, Bethesda, MD, USA

³Department of Pathology and Area Laboratory Services, Tripler Army Medical Center, Honolulu, HI, USA

Running Title: Susceptibility of US Clinical Isolates to Fosfomycin

[#]Address correspondence to Edwin.Kamau.mil@health.mil

Abstract word count: 333

Text word count:

ABSTRACT

Uncomplicated bacteremic urinary tract infections (bUTIs) are common, often caused by *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecalis*, with most encounters treated empirically. As rates of antimicrobial resistance increase, available antibiotic treatment options are dwindling. Novel antibiotics approved for treating bUTIs are limited, leading to a resurgence of interest in older antibiotics, including fosfomycin. In this study, clinical urine samples from patients diagnosed with bUTIs from a military hospital on the Eastern Seaboard of the United States were tested for susceptibility to fosfomycin and comparator antibiotics, including levofloxacin, nitrofurantoin, and trimethoprim-sulfamethoxazole (TMS). A total of 1353 nonduplicate bacterial isolates were tested. The majority were Gram-negative, including 605 non-ESBL and 285 ESBL *E. coli* and 84 non-ESBL and 52 ESBL *K. pneumoniae*. Fosfomycin susceptibility rates were similar for non-ESBL and ESBL *E. coli* (95.9% vs 96.1%) and *K. pneumoniae* (38.1% vs 36.5%). Fosfomycin demonstrated high activity against other Enterobacterales and Gram-positive organisms including *Enterobacter faecalis* and *Staphylococcus aureus*. Interestingly, most fosfomycin non-susceptible isolates were susceptible to other first-line bUTI treatment options, and most isolates that were non-susceptible to other first-line bUTI treatment option were susceptible to fosfomycin. ESBL *K. pneumoniae* isolates were the least susceptible to current first-line treatment options. Fosfomycin Etest demonstrated high sensitivity compared to agar dilution, making it a viable method in resource limited areas. Overall, we demonstrated fosfomycin has high activity against common etiologies that cause bUTIs. Further studies investigating the use of fosfomycin in treating non-*E. coli* bUTI pathogens, as single or combination therapy, is warranted.

IMPORTANCE (150 words max)

Uncomplicated bUTI are often caused by *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecalis*, and treated with antibiotics. As rates of antimicrobial resistance increase, the options available

for treatment are diminishing. Limited novel antibiotics have entered the market leading to a resurgence of interest in older antibiotics, including fosfomycin. In this study, we investigated the susceptibility of bUTI clinical isolates to fosfomycin and current treatment. Isolates were susceptible to fosfomycin at similar or higher rates compared to comparator antibiotics, especially for isolates that produce extended-spectrum beta-lactamases. In addition to *E. coli* and *E. faecalis*, organisms that fosfomycin is FDA approved for, fosfomycin had high activity against other Enterobacterales and Gram-positive organisms including *Staphylococcus aureus*. Since most uncomplicated cystitis is treated empirically, fosfomycin is a reasonable treatment option, either single agent or in combination, supporting the need for randomized control trials to approve treatment of other etiologies, and harmonizing breakpoints across agencies.

INTRODUCTION

Bacteremic urinary tract infections (bUTIs) are common, and can present as asymptomatic or symptomatic uncomplicated, or complicated infections. This distinction is important since it helps guide the choice and duration of antimicrobial treatment (1). Asymptomatic bacteriuria may not warrant treatment, especially in women, and is now recognized as an important contributor to inappropriate antimicrobial use and the emergence of drug resistance (1,2). The most common causes of bUTIs are infections by *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecalis*, complicated by the increasing rate of multidrug resistant (MDR) organisms including the extended-spectrum β -lactamase (ESBL) producing strains of *E. coli* and *K. pneumoniae* (3,4). For uncomplicated acute bacterial cystitis, preferred treatments include nitrofurantoin and trimethoprim/sulfamethoxazole (TMS), and more recently fosfomycin, with fluoroquinolones and beta-lactam agents used as alternative treatment options (1).

Fosfomycin is a bactericidal antibiotic agent with a broad spectrum activity against Gram-negative and Gram-positive pathogens, including MDR Gram-negative pathogens, such as ESBL-producing organisms and carbapenem-resistant Enterobacterales (CRE) (5,6). Discovered in 1969 (7), the oral formulation (fosfomycin trometamol) was approved by the United States Food and Drug Administration (FDA) in 1996, and is one of the recommended first-line treatment options for uncomplicated bUTIs caused by *E. coli* or *E. faecalis* (1,2).

Due to the limited selection of oral antibiotics to treat bUTIs caused by non-*E. coli* pathogens, especially those that are resistant, fosfomycin usage is increasing (1,6). In a meta-analysis of randomized controlled trials (RCTs) assessing the effectiveness and safety for the treatment of cystitis, fosfomycin trometamol was shown to be as effective with clinical and microbiological cure, relapses, and reinfections as comparator antibiotics including quinolones, β -lactams, aminoglycosides, nitrofurantoin, and sulfonamides (8). Furthermore, observational studies have demonstrated fosfomycin is effective in the treatment of MDR infections (9,10), with oral fosfomycin trometamol having similar clinical and microbiological success with carbapenems in the treatment of ESBL-producing *E. coli* (11). More recently, the FOREST randomized trial showed that fosfomycin trometamol was an effective oral step-down therapy for bUTIs due to MDR *E. coli* compared to other oral drugs (12). With the rates of MDR pathogens increasing worldwide including in the US, the use of fosfomycin for the treatment of bUTIs is on the rise and is likely to increase, warranting additional studies.

Given that bacterial susceptibility profiles can differ regionally, we sought to get a better understanding of the *in vitro* activity of fosfomycin and other first-line antibiotics against bUTI pathogens from the mid-Atlantic region of the United States. In this study we determined the efficacy of fosfomycin, nitrofurantoin, levofloxacin, and trimethoprim/sulfamethoxazole (TMS) against clinical bUTI isolates from a military hospital on the US Eastern Seaboard. Furthermore, we sought to examine the efficacy of fosfomycin against MDR isolates as well as species other than *E. coli* and *E. faecalis*.

MATERIALS AND METHODS

This study protocol was approved by the appropriate Human subjects regulatory authority. Investigators adhered to the policies for protection of human subjects as prescribed in 45 Code of Federal Regulation 46.

Bacterial isolates

A total of 1353 nonduplicate bacterial isolates from urine clinical specimens submitted to the clinical laboratory for bUTI testing in our hospital as routine patient standard-of-care were analyzed in this study. Single bacterial colonies obtained from purity plates prepared while setting up automated identification and susceptibility testing on the BD Phoenix system (Becton Dickinson, New Jersey, US) were used for fosfomycin susceptibility testing, which was performed within 24 hours. Fosfomycin susceptibility testing was performed on select isolates at the request of infectious disease clinicians, or randomly selected from the urine bench on the days when fosfomycin testing was performed.

In vitro susceptibility testing

Susceptibilities of all isolates to fosfomycin (Sigma Chemical Co., St. Louis, MO) was determined by the agar dilution method as described by CLSI, with clinical breakpoints for *E. coli* and *E. faecalis* from the urinary tract set at ≤ 64 $\mu\text{g/ml}$ (13,14). For fosfomycin susceptibility testing, plates were prepared using Mueller-Hinton agar (MHA, BBL Microbiology Systems, Cockeysville, MD) supplemented with 25 $\mu\text{g/ml}$ of glucose-6-phosphate and fosfomycin at one of the three concentrations: 64 $\mu\text{g/ml}$; 128 $\mu\text{g/ml}$; 256 $\mu\text{g/ml}$. Bacteria colonies obtained from the purity plates were prepared to 0.5 McFarland and then each isolate spread on four plates; three with fosfomycin (at the three different concentrations) and a control plate that did not contain any antibiotic. Plates were incubated for 16-18 hours at 37°C. The MIC of each antimicrobial agent was defined as the lowest concentration that inhibited visible growth of the organism. Control strains, including *S. aureus* ATCC 29213, *E. coli* ATCC 25922, and *P. aeruginosa* ATCC

27853, were included in each set of tests. Fosfomycin Etest was performed on MHA agar following manufacturer's recommendations (bioMérieux, Durham, NC).

Interpretation of susceptibility test results

Interpretive criteria for susceptibility categories by MIC were applied using the CLSI interpretive criteria for urinary tract isolates of *E. coli* and *E. faecalis* for all the isolates as follows: If bacteria grew in the control plate and plate containing 64 µg/ml fosfomycin, but not in 128 and 256 µg/ml fosfomycin, it was considered susceptible; If bacteria grew in the control plate, and in plates containing 64 µg/ml and 128 µg/ml fosfomycin but not 256 µg/ml, it was considered intermediate; if bacteria grew in all the plates including those containing 256 µg/ml fosfomycin, it was considered resistant. Etest endpoints were read by following the manufacturer's package insert, which permits ≤5 colonies within the ellipse to be ignored.

Data analysis

MIC data for comparator antibiotics were obtained from the BD Phoenix system and fosfomycin data were obtained from agar dilution and Etest. Isolates that were determined to have intermediate susceptibility were considered non-susceptible for analysis. Descriptive statistics were calculated in Excel and Tableau was used for data representation.

RESULTS

Of the 1353 bUTI isolates tested, 89.7% (n=1,213) were Gram-negative and 10.3% (n= 140) were Gram-positive. Species with more than 10 bacterial isolates made up 98% (n=1,326) of all organisms tested, with *E. coli*, *K. pneumoniae*, and *E. faecalis* accounting for the majority (84.0%, n=1,137). The remaining species that composed our results were *Pseudomonas aeruginosa*, *Citrobacter spp*, *Proteus mirabilis*,

Enterococcus faecium, *Enterobacter cloacae*, *Klebsiella aerogenes*, *Klebsiella oxytoca*, and *Staphylococcus aureus* (Figure 1).

Antibiotic Susceptibility of Bacterial Isolates

Minimum inhibitory concentration (MIC) values for each antibiotic (fosfomycin, levofloxacin, TMS, and nitrofurantoin) were obtained in 1,326 (of the total 1,353) bacterial isolates (supplementary file 1). Most species exhibited high rates of susceptibility to fosfomycin (92-100%) except for *P. aeruginosa*, *E. cloacae*, and *Klebsiella spp* which had fosfomycin susceptibilities of less than 56%.

Since *Citrobacter spp* and *P. mirabilis* had high fosfomycin susceptibility rates (96.2% and 92.3%, respectively), and had over 25 isolates, we also evaluated the most common susceptibility patterns in these two species. *Citrobacter spp* overall were more susceptible to the antibiotics tested than *P. mirabilis*. While only 50% of isolates were susceptible to amoxicillin, 92.3% were susceptible to levofloxacin, 84.6% were susceptible to nitrofurantoin, and 88.5% were susceptible to TMS (Supplementary Figure 1). All *Citrobacter spp* isolates were susceptible to at least two antibiotics tested. While only 11.5% of *P. mirabilis* isolates were susceptible to nitrofurantoin, 64.5% were susceptible to levofloxacin, 73.1% were susceptible to TMS, and 96.2% were susceptible to amoxicillin (Supp Figure 1). Like the *Citrobacter spp* isolates, all *P. mirabilis* isolates were susceptible to at least two of the antibiotics tested.

Antibiotic susceptibility in ESBL vs non-ESBL isolates

Susceptibility profiles for fosfomycin and comparator antibiotics of *E. coli* and *K. pneumoniae* isolates identified as ESBL and non-ESBL strains are represented in Figure 2. There were n=605 non-ESBL and n=285 ESBL *E. coli*, n= 84 non-ESBL and n=52 ESBL *K. pneumoniae* isolates.

Fosfomycin susceptibility rates were similar for non-ESBL and ESBL *E. coli* (95.9% vs 96.1%) and *K. pneumoniae*, albeit at much lower rates (38.1% vs 36.5%). For the comparator antibiotics, with exception of nitrofurantoin in *E. coli* where susceptibility rates were similar for non-ESBL and ESBL (97.5% vs 95.8%), percentage susceptibility rates for *E. coli* and *K. pneumoniae* were about twice or more ($\geq 83.0\%$) for non-ESBL compared to ESBL ($\leq 44.0\%$) isolates. Of note, fosfomycin susceptibility profiles appeared to be similar in all species, except for *K. pneumoniae*. The susceptibility profiles of non-ESBL *K. pneumoniae* indicate that levofloxacin and TMS appear to be more effective (Figure 2).

Susceptibility of multiple-drug resistant (MDR) *E. coli* and *K. pneumoniae* isolates to fosfomycin

We then grouped isolates as MDR based on susceptibility to comparator drugs. When we grouped isolates based on non-susceptibility to levofloxacin and TMS, there were 30 (5.0%) non-ESBL and 121 (42.5%) ESBL *E. coli* MDR isolates, of which all but one non-ESBL and seven ESBL were susceptible to fosfomycin (Figure 3A). For ESBL *K. pneumoniae*, there were 19 (36.5%) MDR isolates, of which 5 (26.3%) were susceptible to fosfomycin. There were only two non-ESBL *K. pneumoniae* MDR isolates, and one was resistant to fosfomycin (Figure 3B). When we grouped isolates based on non-susceptibility to levofloxacin, TMS and nitrofurantoin, there were 5 non-ESBL (0.8%) and 5 (1.8%) ESBL *E. coli* MDR isolates, of which all but one non-ESBL and one ESBL were susceptible to fosfomycin (Figure 3A). For ESBL *K. pneumoniae*, there were 17 (32.7%) MDR isolates, of which 5 (29.4%) were susceptible to fosfomycin. Only one of the non-ESBL *K. pneumoniae* isolates was resistant to all three comparator drugs but it was susceptible to fosfomycin (Figure 3B). Finally, we grouped ESBL *E. coli* and *K. pneumoniae* as MDR based on non-susceptibility to the additional antibiotics tested in the automated AST platform including amoxicillin/clavulanate, aztreonam, cefepime and ceftriaxone. Of the 285 ESBL *E. coli* isolates, 89 were MDR, of which 83 (93.3%) were fosfomycin susceptible. There were 52 ESBL *K. pneumoniae* isolates, 27 were MDR, of which 10 (37.0%) were fosfomycin susceptible.

Susceptibility of fosfomycin-resistant isolates to comparator drugs

Of the 25 *E. coli* non-ESBL isolates that were fosfomycin resistant, 23 (92.0%) were susceptible to nitrofurantoin and TMS, and of the 15 isolates that were nitrofurantoin resistant, 13 (86.7%) were susceptible to fosfomycin (Figure 3A). Of the 11 *E. coli* ESBL isolates that were fosfomycin resistant, 10 (90.9%) were susceptible to nitrofurantoin, 3 (27.3%) were susceptible to TMS, and only one (9.1%) was susceptible to levofloxacin. Of the 12 nitrofurantoin-resistant ESBL isolates, 11 (91.7%) were susceptible to fosfomycin, and 6 (50.0%) were susceptible to TMS. Of the 52 fosfomycin resistant non-ESBL *K. pneumoniae* isolates, 20 (38.4%) were susceptible to nitrofurantoin, levofloxacin, and TMS, and 43 (82.7%) were susceptible to levofloxacin and TMS. Fosfomycin resistant ESBL *K. pneumoniae* isolates did not display a predominant susceptibility pattern to comparator drugs (Figure 3B).

Global susceptibility profiles of *E. coli*, *K. pneumoniae* and *E. faecalis*

The global susceptibilities of the isolates to the four antibiotics tested in this study were examined. Isolates were grouped based on the number of antibiotics they were susceptible to. ESBL *K. pneumoniae* displayed the lowest susceptibilities, with 23% of isolates pan-resistant to the four antibiotics tested. Conversely, non-ESBL *E. coli* exhibited the highest susceptibilities, with 71% of isolates pan-susceptible to all antibiotics, and only one was pan-resistant to all the antibiotics tested. The other three groups of isolates displayed at least 50% susceptibility to at least three antibiotics tested (Figure 4).

Common susceptibility patterns in *E. coli*, *K. pneumoniae* and *E. faecalis*

To understand the most common susceptibility patterns, isolates for each species were grouped by identical antibiotic susceptibilities (Figure 5). The most common susceptibility pattern for non-ESBL *E. coli* isolates was susceptible to fosfomycin, levofloxacin, TMS, and nitrofurantoin, which was present in 430 (71.1%) of the isolates. The most common pattern in ESBL *E. coli* was susceptible to fosfomycin and nitrofurantoin but non-susceptible to levofloxacin and TMS, detected in 110 (38.6%) of the isolates.

While three susceptibility patterns were prominent in non-ESBL *K. pneumoniae*, the most common pattern, with 23 (27.4%) isolates, was susceptible to levofloxacin and TMS but non-susceptible to fosfomycin and nitrofurantoin. Interestingly, the susceptibility pattern that was most common in ESBL *K. pneumoniae* was non-susceptible to all four antibiotics tested. ESBL *K. pneumoniae* exhibited the highest number of susceptibility patterns, 14 out of the possible 16 patterns represented (Figure 3). The majority of *E. faecalis* isolates (66 [71.0%]) were susceptible to fosfomycin, levofloxacin, and nitrofurantoin but non-susceptible to TMS.

Comparison of agar dilution and Etest outcomes

Given that agar dilution (AD) is time and material-intensive, we tested if the Etest, which may be more practical for many labs performing surveillance, especially in resource-limited areas, could provide accurate results. Fosfomycin susceptibility profiles were established using the Etest in the following bacterial isolates: 477 *E. coli*, of which 34 were ESBLs; 96 *K. pneumoniae*, of which 11 were ESBLs; and 45 *E. faecalis*. There was a dramatic range in MICs (Figure 6), which led to more considerable than expected disparities between the median and average MICs (Table 1). Overall *E. coli* was highly susceptible compared to *K. pneumoniae* for non-ESBLs (99.8% vs. 50.6%) and ESBLs (91.0% vs. 45.5%) and *E. faecalis* had high susceptibility rates (88.9%) (Table 1). Of the 116 isolates tested for fosfomycin susceptibility by both Etest and AD, 116 (100.0%) were identified as susceptible by AD but only 109 (94.0%) were identified as susceptible by Etest. Three misidentified isolates had MICs greater than 256 µg/mL.

Table 1. Isolate susceptibility to fosfomycin determined by the Etest

	Non-ESBL		ESBL		
	<i>E. coli</i>	<i>K. pneumoniae</i>	<i>E. coli</i>	<i>K. pneumoniae</i>	<i>E. faecalis</i>
Median	1	96	1.5	64	32

Average	15.2	255.8	8.22	81.8	40.2
Standard Deviation	109.3	372.5	24.1	57.3	28.0
Percent susceptible	99.8	50.6	91.0	45.5	88.9
Percent susceptible (AD)	95.9	36.4	96.4	37.3	98.0

DISCUSSION

In this study, we evaluated fosfomycin activity against common bUTI organisms collected from a military hospital located in the Eastern Seaboard of the United States using CLSI breakpoints for *E. coli* and *E. faecalis*. In addition to showing high activity against these two organisms, fosfomycin also displayed high activity against other common bUTI organisms, including Enterobacterales (*Citrobacter spp* and *P. mirabilis*) and Gram-positive organisms (*S. aureus* and *E. faecium*). Further, fosfomycin displayed high activity against ESBL and MDR *E. coli* isolates, with similar susceptibility rates as those for non-ESBL isolates. Nitrofurantoin displayed similarly high activity against *E. coli* as fosfomycin. Interestingly, most fosfomycin non-susceptible isolates were susceptible to nitrofurantoin, and most nitrofurantoin non-susceptible isolates were susceptible to fosfomycin. Fosfomycin displayed least activity against *K. pneumoniae*, both non-ESBL and ESBL isolates. Fosfomycin non-susceptible non-ESBL *K. pneumoniae* were highly susceptible to levofloxacin and TMS but not nitrofurantoin. Fosfomycin also displayed low activity against *K. aerogenes*, *E. cloacae* and *P. aeruginosa*. The susceptibility rates in our study corroborated a recent study which showed *P. aeruginosa* with susceptibility rate of 40.4% to fosfomycin (15).

As a primary or step-down bUTI treatment, fosfomycin has been shown to have high clinical, microbiological, and *in vitro* activity against MDR *E. coli*, including those harboring metallo- β -lactamases (12, 16-26). Oral fosfomycin tromethamine is FDA-approved for single-dose treatment of uncomplicated

bUTI (23,27). As the predominant bUTI pathogen, most published studies investigating clinical, microbiological, and *in vitro* activity of fosfomycin have primarily focused on *E. coli* (28). There are however studies that have also investigated activity of fosfomycin against other common bUTI species. A study by Mezzatesta *et al.*, found in addition to having high activity against ESBL *E. coli*, fosfomycin had high *in vitro* activity against ESBL *P. mirabilis* and methicillin-resistant *S. saprophyticus* (5). Other studies have also demonstrated high fosfomycin *in vitro* activity against Enterobacterales, including *Proteus spp*, *Enterobacter spp*, *Serratia spp*, and *Citrobacter spp* (28,29). These studies corroborate part of our data where we demonstrated high fosfomycin *in vitro* activity against *P. mirabilis* and *Citrobacter spp* but not *Enterobacter*. Further, similarly to our study, studies have demonstrated that fosfomycin retains high *in vitro* activity against bacterial isolates that are non-susceptible to other first-line treatments for bUTI (28,29).

Fosfomycin *in vitro* activity against *K. pneumoniae* seems to vary widely between studies but remains consistently lower than that of most other Enterobacterales (5, 27-30). Interestingly, high clinical and microbiological cures have been attained in patients treated with fosfomycin due to bUTI caused by *K. pneumoniae* (31-33). Although the epidemiology and susceptibility of different organisms may vary based on the country and region, these data strongly suggest fosfomycin is a highly active antibiotic against the most common causes of bUTI and has a high clinical cure rate. This is important since most uncomplicated bUTI are treated empirically (34). Therefore, an antibiotic that provides broad-spectrum activity, including activity against MDR organisms with good clinical outcomes, is a reasonable treatment option. Further, fosfomycin is a highly viable option as a step-down treatment (12,18,20). RCTs will be invaluable in investigating fosfomycin effectiveness in treating other common bUTI pathogens including *K. pneumoniae*, especially in regions with high rates of MDR organisms.

Fosfomycin tromethamine is an antibacterial phosphonic acid that inhibits bacterial cell wall formation by interfering with peptidoglycan synthesis (35). *In vitro* synergy between fosfomycin and other

antibiotics has been demonstrated, which may be useful as an alternative treatment option, especially for MDR organisms including *K. pneumoniae*, *P. aeruginosa*, *Acinetobacter baumannii* and methicillin-resistant *S. aureus* (36). The synergistic effect between fosfomycin and β -lactam antibiotics is proposed to arise from the inhibition of cell wall synthesis at separate steps, and ciprofloxacin is due to ciprofloxacin-mediated damage to the outer membrane, which increases the penetration and activity of fosfomycin (35,37-38). In *P. aeruginosa*, *in vitro* studies demonstrated synergy between fosfomycin and a variety of other antibiotics, including aztreonam, cefepime, meropenem, imipenem, ceftazidime, gentamycin, amikacin, ciprofloxacin, and others (37-40). Further, the synergistic activity of fosfomycin, ciprofloxacin, and gentamicin against *E. coli* and *P. aeruginosa* biofilms has been demonstrated (41), making it a reasonable treatment option for patients with catheters. RCTs investigating fosfomycin as a combination therapy have shown higher clinical and microbiological success rates in many different infections, including sepsis/bacteremia and respiratory tract infections (25, 42,43). However, to the best of our knowledge, RCTs investigating fosfomycin as a combination therapy in treating UTIs have not been conducted (42). In our study, with the exception of one isolate, all fosfomycin-resistant *E. coli* were susceptible to either all or at least one of the comparator UTIs first-line or alternate drugs. Clinical studies have compared the efficacy of fosfomycin to comparator UTI first-line drugs and have shown it to be a valuable alternative option (24, 42, 44-47). In a study investigating treatment patterns and clinical outcomes among females with uncomplicated bUTI in Germany that were empirically treated, the incidence of recurrent infection in the 6-month post-index period was higher in patients with *E. coli* that were resistant to one of the first-line treatments (48). With antimicrobial susceptibility rates and epidemiology of bUTI pathogens different and rapidly changing from one region to another, robust research with well-designed double-blinded RCTs investigating the use of fosfomycin as a combination therapy for the treatment of bUTIs, especially in patients with recurrent infections, is warranted.

Similar to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the Clinical and Laboratory Standards Institute (CLSI) recognizes AD as the reference method for fosfomycin susceptibility testing for *E. coli* and *E. faecalis* (13,49,50). AD is a labor- and time-intensive methodology, which has led to many laboratories using either disk diffusion, which is only approved for *E. coli* from urine samples by CLSI (50), or Etest, which is only approved by EUCAST (49) but not CLSI. This is further complicated by differences in breakpoints between CLSI and EUCAST, which also varies by specimen types (51). Etests, based on a combination of dilution and diffusion testing, offer valuable solutions since they provide MICs. However, there are concerns about the accuracy of Etest results, which can also be challenging to interpret due to micro- and macro-colonies (51, 52). A recent new formulation of the fosfomycin Etest showed high accuracy, which is vital as an alternative to AD (49-51). In our study, using AD as a reference method, data produced using Etest had sensitivity closer to 95%, making it a viable method for fosfomycin testing in addition to disk diffusion. Etests provide MIC values, which may be helpful in clinical decisions if the recently developed novel Etest formulations perform consistently in other laboratories' hands (51). In that case, CLSI should support studies validating the use of Etest as a susceptibility testing option for fosfomycin, given the numerous challenges of using AD in susceptibility testing and the limitations of disk diffusion.

In conclusion, *in vitro* data from our patient population demonstrate that in addition to *E. coli*, fosfomycin has high activity against several of the most common Gram-negative and Gram-positive bUTI pathogens, including those that are MDR. Furthermore, we've shown that the Etest is a viable alternative for fosfomycin susceptibility testing. However, RCTs investigating fosfomycin for the treatment of bUTIs due to organisms other than *E. coli* are lacking whereas clinical, microbiologic, and *in vitro* data strongly suggest this is a viable treatment option. Since bUTIs are among the most common bacterial infections worldwide, occurring in both community and in healthcare settings, and most are usually treated empirically (34), having an effective treatment option against MDR pathogens will play

an essential role in managing bUTIs worldwide and antimicrobial stewardship programs. RCTs investigating the use of fosfomycin in treating non-*E. coli* bUTI pathogens and as a combination therapy for treating UTIs, especially in patients with recurrent infections, are long overdue.

ACKNOWLEDGMENTS

Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily reflect the official policy of the Department of Defense, Department of Army, US Army Medical Department, Defense Health Agency, or the US Government. The study protocol was approved by the appropriate Human subjects regulatory authority. Investigators adhered to the policies for protection of human subjects as prescribed in 45 Code of Federal Regulation 46.

Conflicts of interest: The authors declare no conflicts of interest.

Ethical statement: The institution's ethical review board and the human research protection office at the Defense Health Agency and Tripler Army Medical Center reviewed and approved this study.

REFERENCES

1. Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. *Microbiol Spectr*. 2016 Oct;4(5). doi: 10.1128/microbiolspec.UTI-0002-2012. PMID: 27780014.
2. Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves B, Hooton TM, Juthani-Mehta M, Knight SL, Saint S, Schaeffer AJ, Trautner B, Wullt B, Siemieniuk R. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2019 May 2;68(10):e83-e110. Doi: 10.1093/cid/ciy1121. PMID: 30895288.
3. Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I. Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012. *Infect Dis Ther*. 2017 Jun;6(2):233-243. doi: 10.1007/s40121-017-0150-5. Epub 2017 Mar 11. PMID: 28285420; PMCID: PMC5446363.
4. Mosime LB, Newton-Foot M, Nel P. Fosfomycin resistance in community-acquired urinary pathogens from Western Cape, South Africa. *S Afr J Infect Dis*. 2022 Jan 19;37(1):321. doi: 10.4102/sajid.v37i1.321. PMID: 35169586; PMCID: PMC8831924.
5. Mezzatesta ML, La Rosa G, Maugeri G, Zingali T, Caio C, Novelli A, Stefani S. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens. *Int J Antimicrob Agents*. 2017 Jun;49(6):763-766. doi: 10.1016/j.ijantimicag.2017.01.020. Epub 2017 Apr 5. PMID: 28390962.
6. Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. *Int J Antimicrob Agents*. 2016 Apr;47(4):269-85. doi: 10.1016/j.ijantimicag.2016.02.001. Epub 2016 Feb 24. PMID: 27013000.
7. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S. 1969. Phosphonomycin, a new antibiotic produced by strains of streptomyces. *Science* 166:122–123. doi: 10.1126/science.166.3901.122.
8. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. *Clin Microbiol Rev*. 2016 Apr;29(2):321-47. doi: 10.1128/CMR.00068-15. PMID: 26960938; PMCID: PMC4786888.
9. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended-spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infections. *Int J Antimicrob Agents*. 2007 Jan;29(1):62-5. doi: 10.1016/j.ijantimicag.2006.08.039. PMID: 17189097.
10. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A. Community infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *Arch Intern Med*. 2008 Sep 22;168(17):1897-902. doi: 10.1001/archinte.168.17.1897. PMID: 18809817.
11. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, Arda B, Ulusoy S. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing *Escherichia coli*-related complicated lower urinary tract infection. *J Chemother*. 2010 Oct;22(5):355-7. doi: 10.1179/joc.2010.22.5.355. PMID: 21123160.
12. Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Giner-Oncina L, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Alvarez RM, Dueñas CJ, Calvo-Montes J, Silva JT, Cárdenes MA, Lecuona M, Pomar V, Valiente de Santis L, Yagüe-Guirao G, Lobo-Acosta MA, Merino-Bohórquez V, Pascual A, Rodríguez-Baño J; REIPI-GEIRAS-FOREST group. Effectiveness of Fosfomycin for the

- 377 Treatment of Multidrug-Resistant *Escherichia coli* Bacteremic Urinary Tract Infections: A
378 Randomized Clinical Trial. *JAMA Netw Open*. 2022 Jan 4;5(1):e2137277. doi:
379 10.1001/jamanetworkopen.2021.37277. PMID: 35024838; PMCID: PMC8759008
- 380 13. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial
381 susceptibility testing; twenty-third informational supplement. M100-S23. Clinical and Laboratory
382 Standards Institute, Wayne, PA.
- 383 14. Clinical and Laboratory Standards Institute 2009. Methods for dilution susceptibility tests for
384 bacteria that grow aerobically; approved standard. M7-A8, 8th ed Clinical and Laboratory
385 Standards Institute, Wayne, PA
- 386 15. Smith EC, Brigman HV, Anderson JC, Emery CL, Bias TE, Bergen PJ, Landersdorfer CB, Hirsch EB.
387 Performance of Four Fosfomycin Susceptibility Testing Methods against an International
388 Collection of Clinical *Pseudomonas aeruginosa* Isolates. *J Clin Microbiol*. 2020 Sep
389 22;58(10):e01121-20. doi: 10.1128/JCM.01121-20. PMID: 32669380; PMCID: PMC7512173.
- 390 16. Sojo-Dorado J, López-Hernández I, Hernández-Torres A, Retamar-Gentil P, Merino de Lucas E,
391 Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí
392 L, Borrell N, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Álvarez RM, Dueñas CJ,
393 Calvo-Montes J, Lecuona M, Pomar V, Borreguero I, Palomo-Jiménez V, Docobo-Pérez F, Pascual
394 Á, Rodríguez-Baño J; CIBERINFEC-GEIRAS-FOREST group. Effectiveness of fosfomycin trometamol
395 as oral step-down therapy for bacteraemic urinary tract infections due to MDR *Escherichia coli*: a
396 post hoc analysis of the FOREST randomized trial. *J Antimicrob Chemother*. 2023 Jun 1:dkad147.
397 doi: 10.1093/jac/dkad147. Epub ahead of print. PMID: 37260299.
- 398 17. Bakthavatchalam YD, Shankar A, Manokaran Y, Walia K, Veeraraghavan B. Can fosfomycin be an
399 alternative therapy for infections caused by *E. coli* harbouring dual resistance: NDM and four-
400 amino acid insertion in PBP3? *JAC Antimicrob Resist*. 2023 Mar 4;5(2):dlad016. doi:
401 10.1093/jacamr/dlad016. PMID: 36880086; PMCID: PMC9985326.
- 402 18. Burgos J, Hoyos-Mallecot Y, Ferre-Losa C, Arando M, Monforte A, Pumarola T, Los-Arcos I, Falcó V.
403 Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant
404 Enterobacterales. *Microbiol Spectr*. 2023 Sep 22;11(5):e0213623. doi: 10.1128/spectrum.02136-
405 23. Epub ahead of print. PMID: 37737627; PMCID: PMC10580941.
- 406 19. Vahiddastjerdi M, Vaghar ME, Dashtaki SG. Evaluation of Efficacy of Fosfomycin for the
407 Treatment of Patients with Lower Urinary Tract Infections (UTIs). *Maedica (Bucur)*. 2023
408 Dec;18(4):593-597. doi: 10.26574/maedica.2023.18.4.593. PMID: 38348083; PMCID:
409 PMC10859210.
- 410 20. Ten Doesschate T, Kuiper S, van Nieuwkoop C. 2021. FORECAST study team. Fosfomycin versus
411 ciprofloxacin as oral stepdown treatment for *Escherichia coli* febrile urinary tract infection in
412 women: a randomized, placebo-controlled, double blind, multicenter trial. *Clin Infect*
413 *Dis:ciab934*.
- 414 21. Falagas M.E., Kanellopoulou M.D., Karageorgopoulos D.E., Dimopoulos G., Rafailidis P.I.,
415 Skarmoutsou N.D., Papafrangas E.A. Antimicrobial susceptibility of multidrug-resistant Gram
416 negative bacteria to fosfomycin. *Eur. J. Clin. Microbiol. Infect. Dis*. 2008;27:439–443. doi:
417 10.1007/s10096-007-0456-4. [PubMed] [CrossRef] [Google Scholar]
- 418 22. Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S.
419 Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized
420 controlled trials. *J Antimicrob Chemother*. 2010 Sep;65(9):1862-77. doi: 10.1093/jac/dkq237.
421 Epub 2010 Jun 29. PMID: 20587612.

23. Falagas M.E., Maraki S., Karageorgopoulos D.E., Kastoris A.C., Mavromanolakis E., Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. *Int. J. Antimicrob. Agents*. 2010;35:240–243. doi: 10.1016/j.ijantimicag.2009.10.019. [PubMed] [CrossRef] [Google Scholar]
24. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β -lactamase producing, Enterobacteriaceae infections: A systematic review. *Lancet Infect. Dis*. 2010;10:43–50. doi: 10.1016/S1473-3099(09)70325-1. [PubMed] [CrossRef] [Google Scholar]
25. Michalopoulos A., Virtzili S., Rafailidis P., Halevelakis G.H., Damala M., Falagas M. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant *Klebsiella pneumoniae* in critically ill patients: A prospective evaluation. *Clin. Microbiol. Infect.* 2010;16:184–186. doi: 10.1111/j.1469-0691.2009.02921.x. [PubMed] [CrossRef] [Google Scholar]
26. Dinh A., Salomon J., Bru J.P., Bernard L. Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria. *Scand. J. Infect. Dis*. 2012;44:182–189. doi: 10.3109/00365548.2011.616221.
27. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, Hsueh PR. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. *Antimicrob Agents Chemother*. 2011 Sep;55(9):4295-301. doi: 10.1128/AAC.00349-11. Epub 2011 Jun 13. PMID: 21670185; PMCID: PMC3165352
28. Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. *Int J Infect Dis*. 2013 Nov;17(11):e966-70. doi: 10.1016/j.ijid.2013.04.005. Epub 2013 Jun 3. PMID: 23742831
29. Fajfr M, Louda M, Paterová P, Ryšková L, Pacovský J, Košina J, Žemličková H, Brodčák M. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study. *BMC Urol*. 2017 Apr 26;17(1):33. doi: 10.1186/s12894-017-0222-6. PMID: 28446177; PMCID: PMC5406914
30. Linsenmeyer K, Strymish J, Weir S, Berg G, Brecher S, Gupta K. Activity of Fosfomycin against Extended-Spectrum- β -Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients. *Antimicrob Agents Chemother*. 2015 Nov 23;60(2):1134-6. doi: 10.1128/AAC.02614-15. PMID: 26596940; PMCID: PMC4750673
31. Vahiddastjerdi M, Vaghar ME, Dashtaki SG. Evaluation of Efficacy of Fosfomycin for the Treatment of Patients with Lower Urinary Tract Infections (UTIs). *Maedica (Bucur)*. 2023 Dec;18(4):593-597. doi: 10.26574/maedica.2023.18.4.593. PMID: 38348083; PMCID: PMC10859210.
32. Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. *Int J Antimicrob Agents*. 1998 Apr;10(1):39-47. doi: 10.1016/S0924-8579(98)00021-1. PMID: 9624542.
33. Karimi A, Afrakhteh M, Aghazadeh Naeini A, Amiri Z. A Comparison of Cephalexin with Fosfomycin Trometanol (monurol) in the treatment of pregnant women with lower urinary tract. *Yafteh*. 2012;13:17–22.

34. Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary Tract Infections: The Current Scenario and Future Prospects. *Pathogens*. 2023 Apr 20;12(4):623. doi: 10.3390/pathogens12040623. PMID: 37111509; PMCID: PMC10145414.
35. Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J, Kamerling IMC. Fosfomycin: Pharmacological, Clinical and Future Perspectives. *Antibiotics (Basel)*. 2017 Oct 31;6(4):24. doi: 10.3390/antibiotics6040024. PMID: 29088073; PMCID: PMC5745467.
36. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. *Eur J Clin Pharmacol*. 2010 Apr;66(4):359-68. doi: 10.1007/s00228-010-0794-5. Epub 2010 Feb 26. PMID: 20186407.
37. Samonis G., Maraki S., Karageorgopoulos D.E., Vouloumanou E.K., Falagas M.E. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant *Klebsiella pneumoniae*, *Escherichia coli*, and *Pseudomonas aeruginosa* clinical isolates. *Eur. J. Clin. Microbiol. Infect. Dis*. 2012;31:695–701. doi: 10.1007/s10096-011-1360-5.
38. Yamada S., Hyo Y., Ohmori S., Ohuchi M. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of *Pseudomonas aeruginosa*. *Chemotherapy*. 2007;53:202–209. doi: 10.1159/000100811.
39. Okazaki M., Suzuki K., Asano N., Araki K., Shukuya N., Egami T., Higurashi Y., Morita K., Uchimura H., Watanabe T. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant *Pseudomonas aeruginosa* isolates using the efficacy time index assay. *J. Infect. Chemother*. 2002;8:37–42. doi: 10.1007/s101560200004.
40. Tessier F., Quentin C. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against *Pseudomonas aeruginosa*. *Eur. J. Clin. Microbiol. Infect. Dis*. 1997;16:159–162. doi: 10.1007/BF01709477
41. Wang L, Di Luca M, Tkhalishvili T, Trampuz A, Gonzalez Moreno M. Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against *Escherichia coli* and *Pseudomonas aeruginosa* Biofilms. *Front Microbiol*. 2019 Nov 6;10:2522. doi: 10.3389/fmicb.2019.02522. PMID: 31781056; PMCID: PMC6853019.
42. Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. *Clin Microbiol Infect*. 2017 Jun;23(6):363-372. doi: 10.1016/j.cmi.2016.12.005. Epub 2016 Dec 9. PMID: 27956267.
43. Shaw E, Miró JM, Puig-Asensio M, Pigrau C, Barcenilla F, Murillas J, Garcia-Pardo G, Espejo E, Padilla B, Garcia-Reyne A, Pasquau J, Rodríguez-Baño J, López-Contreras J, Montero M, de la Calle C, Pintado V, Calbo E, Gasch O, Montejo M, Salavert M, Garcia-Pais MJ, Carratalà J, Pujol M; Spanish Network for Research in Infectious Diseases (REIPI RD12/0015); Instituto de Salud Carlos III, Madrid, Spain; GEIH (Hospital Infection Study Group). Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. *BMJ Open*. 2015 Mar 11;5(3):e006723. doi: 10.1136/bmjopen-2014-006723. PMID: 25762232; PMCID: PMC4360784.
44. Hassan MM, Malik M, Saleem R, Saleem A, Zohaib K, Malik AY, Javaid M. Efficacy of Single Dose of Fosfomycin Versus a Five-Day Course of Ciprofloxacin in Patients With Uncomplicated Urinary Tract Infection. *Cureus*. 2022 May 9;14(5):e24843. doi: 10.7759/cureus.24843. PMID: 35702450; PMCID: PMC9177222

45. Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. *JAMA*. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627. PMID: 29710295; PMCID: PMC6134435.
46. Grant R, Büchler A, Flight W, Huang C, Ferrinho D, Janmohamed S, Mulgirigama A, Godycki-Cwirko M, Leibovici L, Huttner A, Harbarth S. Impact of the 2019 Food and Drug Administration Guidance for Uncomplicated Urinary Tract Infection on Treatment Response Rates: A Reanalysis of a Clinical Trial of Nitrofurantoin vs Fosfomycin. *Open Forum Infect Dis*. 2023 Nov 4;10(11):ofad557. doi: 10.1093/ofid/ofad557. PMID: 38023546; PMCID: PMC10661658.
47. Porreca A, D'Agostino D, Romagnoli D, Del Giudice F, Maggi M, Palmer K, Falabella R, De Berardinis E, Sciarra A, Ferro M, Artibani W, Mirone V, Busetto GM. The Clinical Efficacy of Nitrofurantoin for Treating Uncomplicated Urinary Tract Infection in Adults: A Systematic Review of Randomized Control Trials. *Urol Int*. 2021;105(7-8):531-540. doi: 10.1159/000512582. Epub 2021 Feb 3. PMID: 33535221.
48. Naber KG, Wagenlehner F, Kresken M, Cheng WY, Catillon M, Duh MS, Yu L, Khanal A, Mulgirigama A, Joshi AV, Ju S, Mittrani-Gold FS. *Escherichia coli* resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study. *Sci Rep*. 2023 Jul 26;13(1):12077. doi: 10.1038/s41598-023-38919-8. PMID: 37495602; PMCID: PMC10372039.
49. European Committee on Antimicrobial Susceptibility Testing. 2022. Breakpoint tables for interpretation of MICs and zone diameters; version 12.0. <http://www.eucast.org>
50. Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing; thirty-second informational supplement. M100-S32. Clinical and Laboratory Standards Institute, Wayne, PA.
51. Goer A, Blanchard LS, Van Belkum A, Loftus KJ, Armstrong TP, Gattermann SG, Shortridge D, Olson BJ, Meece JK, Fritsche TR, Pompilio M, Halimi D, Franceschi C. Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species. *J Clin Microbiol*. 2022 Jul 20;60(7):e0002122. doi: 10.1128/jcm.00021-22. Epub 2022 Jun 23. PMID: 35736011; PMCID: PMC9297813.
52. van Mens SP, Ten Doesschate T, Kluytmans-van den Bergh MFQ, Mouton JW, Rossen JWA, Verhulst C, Bonten MJM, Kluytmans JAJW. Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement. *Int J Antimicrob Agents*. 2018 Nov;52(5):678-681. doi: 10.1016/j.ijantimicag.2018.06.014. Epub 2018 Jun 27. PMID: 29958976.

FIGURES




Figure 1. Susceptibility of bacteria isolates from urinary tract infections to fosfomycin. Bacterial isolates (n=1,326) were tested for susceptibility to fosfomycin. *E. coli*, *K. pneumoniae* and *E. faecalis* represented the majority of isolates. Species with more than 10 isolates are displayed (note, different *Citrobacter* species are combined); data shows species, number of isolates tested, and percent susceptible to fosfomycin. EC *Enterobacter cloacae*; KA *Klebsiella aerogenes*; SA *Staphylococcus aureus*; KO *Klebsiella oxytoca*.




Figure 2. Clinical isolates of *E. coli* and non-ESBL *K. pneumoniae* are susceptible to fosfomycin at similar, or higher rates, than comparator antibiotics. The agar dilution method was used to test whether clinical isolates were susceptible to fosfomycin. Comparator antibiotic susceptibilities were tested using broth dilution. UTI isolates of *E. coli* (n=890), *K. pneumoniae* (n= 136), and *E. faecalis* (n=93) were tested for susceptibilities to fosfomycin and comparator antibiotics. Isolates of *E. coli* and *K. pneumoniae* were separated by ESBL and non-ESBL to observe antibiotic susceptibilities.




Figure 3. Numerical breakdown of the susceptibility patterns for all isolates tested. Columns depict the number of isolates that are fosfomycin susceptible. Rows further delineate susceptibility to nitrofurantoin, levofloxacin and TMS for *E. coli*, n=890 (A), *K. pneumoniae*, n=136 (B), and *E. faecalis* n=93 (C). fos (fosfomycin susceptible), lev (levofloxacin susceptible), tms (trimethoprim and sulfamethoxazole susceptible), nitro (nitrofurantoin susceptible). RFOS (fosfomycin non-susceptible), RLEV (levofloxacin non-susceptible), RTMS (trimethoprim and sulfamethoxazole non-susceptible), RNITRO (nitrofurantoin non-susceptible).




Figure 4. Global susceptibility of isolated strains to the antibiotics tested. Isolates were organized into groups based on the number of antibiotics they were susceptible to. Non-ESBL *E.coli* strains were the most susceptible to the antibiotics tested while ESBL *K. pneumoniae* strains were the least susceptible. Dark purple indicates susceptibility to none of the antibiotics tested and gray indicates strains that were susceptible to four antibiotics.




Figure 5. Most common antibiotic susceptibility profiles of tested isolates. Antibiotic susceptibility profiles of all isolates (n=1,119) tested were examined and profiles that had 10 or more isolates are depicted here. The larger the circle the more isolates were in that group. fos (fosfomycin susceptible), lev (levofloxacin susceptible), tms (trimethoprim and sulfamethoxazole susceptible), nitro (nitrofurantoin susceptible). RFOS (fosfomycin non-susceptible), RLEV (levofloxacin non-susceptible), RTMS (trimethoprim and sulfamethoxazole non-susceptible), RNITRO (nitrofurantoin non-susceptible). Number of isolates for each profile included.





Figure 6. Distribution of fosfomycin MICs. MICs for fosfomycin were determined by E test for (A) *E. coli*, (B) *K. pneumoniae*, and (C) *E. faecalis*.

Supplementary Figures



Supplementary figure 1. Susceptibilities of clinical isolates to fosfomycin and comparator antibiotics.

The agar dilution method was used to test whether clinical isolates were susceptible to fosfomycin.

Comparator antibiotic susceptibilities were tested using broth dilution. UTI isolates of *E. coli* (n=890), *K.*

pneumoniae (n= 136), and *E. faecalis* (n=93), *P. aeruginosa* (n=28), *Citrobacter* (n=26), *P. mirabilis*

(n=25), *E. faecium* (n=22), *E. cloacae* (n=20), *K. aerogenes* (n=19) were tested for susceptibilities to

fosfomycin and comparator antibiotics. *E. faecalis* was not tested for amoxicillin susceptibility and *E.*

faecium was not tested for nitrofurantoin, TMS, or amoxicillin susceptibilities.